We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Drugs May Target C. difficile Toxin Producing Genes

By Biotechdaily staff writers
Posted on 18 Sep 2007
Bacteriologists have identified a protein regulator of toxin production in the gastrointestinal pathogen Clostridium difficile and suggest that it may be an attractive drug target for controlling the disease.

Investigators at the Tufts University School of Medicine (Boston, MA, USA) focused on the protein produced by the CodY gene, a global regulator of gene expression in Gram-positive bacteria. More...
They genetically engineered a strain of C. difficile lacking the CodY gene and compared its toxin production to the wild type strain. Results published in the August 28, 2007 online edition of Molecular Microbiology revealed that the mutant strain produced much higher levels of toxin.
To determine the mode of action of CodY protein the investigators mixed the protein with DNA extracted from C. difficile. They found that the protein bound with high affinity to a DNA fragment containing the promoter region of the tcdR gene, which encodes a sigma factor permitting RNA polymerase to recognize promoters of the two major toxin genes as well as its own promoter. CodY also bound, but with low affinity, to the toxin gene promoters, suggesting that the regulation of toxin gene expression by CodY occurred primarily through direct control of tcdR gene expression. Binding of CodY to the tcdR promoter region was enhanced in the presence of GTP (guanosine triphosphate) and branched-chain amino acids, suggesting a link between nutrient limitation and the expression of C. difficile toxin genes.

"The C. difficile bacteria only produce toxins when they are in need of food,” explained senior author Dr. Abraham Sonenshein, professor of microbiology at the Tufts University School of Medicine. "We found that the CodY protein, in essence, monitors the hunger level of C. difficile, preventing toxin production when the bacteria have enough to eat.”

"When CodY senses that the cell has enough nutrients, it binds to this gene region, and prevents the bacterium from making toxin,” said Dr. Sonenshein. "Conversely, when food is scarce, the CodY protein does not bind to these genes, allowing C. difficile to make the toxins needed to attack intestinal cells. It is possible that, based on our findings, a new drug could be developed that would trick CodY into thinking there is enough fuel for the bacteria, causing CodY to remain bound to the toxin gene region and thus suppressing toxin production.”


Related Links:
Tufts University School of Medicine

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
hCG Whole Blood Pregnancy Test
VEDALAB hCG-CHECK-1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.